AI Science Tracker
EN

Integrative bioinformatics analysis and experimental validation of key biomarkers driving the progression of cirrhotic portal hypertension

Department of Gastroenterology, The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University), Wuxi, China; Department of Pathology, The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University), Wuxi, China; Experimental Center, The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University), Wuxi, China; Department of Hepatology, The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University), Wuxi, China; Department of Urology, Xishan People's Hospital of Wuxi City, Wuxi, China · 30 Apr 2025 · medicine

Discovery

Integrative bioinformatics analysis and experimental validation of key biomarkers driving the progression of cirrhotic portal hypertension

Source check: Source checked. Not independent scientific confirmation.

Finding: The study reports OIT3 and LOXL1 as candidate cirrhotic portal-hypertension biomarkers and links them with disease-associated expression and pathways. The authors report an independent GEO cohort and clinical-tissue RT-qPCR/IHC. OIT3 replicated, while LOXL1 expression and diagnostic performance did not replicate adequately (validation AUC 0.6169); this limits the claim.

Technology: LASSO, random forest and SVM-RFE screened transcriptomic candidate genes; their intersection selected OIT3 and LOXL1 for subsequent testing.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
LASSO, random forest and SVM-RFE screened transcriptomic candidate genes; their intersection selected OIT3 and LOXL1 for subsequent testing.
Test and result
The study reports OIT3 and LOXL1 as candidate cirrhotic portal-hypertension biomarkers and links them with disease-associated expression and pathways.
Limitation / still unknown
The authors report an independent GEO cohort and clinical-tissue RT-qPCR/IHC. OIT3 replicated, while LOXL1 expression and diagnostic performance did not replicate adequately (validation AUC 0.6169); this limits the claim.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://peerj.com/articles/19360

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary source full text Methods and Results; version/date checked against bibliographic record..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.